Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

AGIO
Agios Pharmaceuticals, Inc.
stock NASDAQ

At Close
May 12, 2025 3:59:49 PM EDT
29.14USD+6.662%(+1.82)476,362
29.12Bid   29.17Ask   0.05Spread
Pre-market
May 12, 2025 8:45:30 AM EDT
27.97USD+2.379%(+0.65)100
After-hours
May 12, 2025 4:38:30 PM EDT
29.14USD0.000%(0.00)391
OverviewOption ChainMax Pain
Options
Options
Option Chain
Max Pain
HistoricalExchange VolumeDark Pool LevelsDark Pool Prints
Exchanges
Exchanges
Exchange Volume
Dark Pool Levels
Dark Pool Prints
Short VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)
Shorts
Shorts
Short Volume
Short Interest - Daily
Short Interest
Borrow Fee (CTB)
Failure to Deliver (FTD)
TrendsNews
News
More
Trends
News
Jan 10, 2022
07:29AM EST  Agios Pharma Lists 2022 Milestones   Benzinga
07:00AM EST  Company Expects to Receive FDA Regulatory Decision for Mitapivat as a Potential Treatment for Adults with PK Deficiency in February   GlobeNewswire Inc
Dec 22, 2021
07:00AM EST  Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that the company is scheduled to present at the virtual 40th AnnualJ.P. Morgan Healthcare ConferenceonWednesday, January 12, 2022,at7:30 a.m. ET.   GlobeNewswire Inc
Dec 14, 2021
09:37AM EST  Agios Presents Mitapivat Long-Term Data On Hemoglobin Response, Transfusion Burden   Benzinga
Dec 13, 2021
06:15PM EST  Additional Data Presented at ASH Support the Potential of Mitapivat to Improve Ineffective Erythropoiesis and Iron Overload and Stabilize Bone Mineral Density in PK DeficiencyPatients   GlobeNewswire Inc
10:32AM EST  Agios Presents Mitapivat Data Highlighting Long-Term Safety Profile And Durable Improvement In Hemoglobin And Markers Of Hemolysis In Non-Transfusion-Dependent - And -Thalassemia At ASH 2021 Meeting   Benzinga
10:30AM EST  Global Phase 3 ENERGIZE and ENERGIZE-T Studies of Mitapivat in Transfusion-dependent and Non-transfusion-dependent - and -Thalassemia Initiated   GlobeNewswire Inc
07:19AM EST  Agios Announces Data From Investigator-led Studies Of Mitapivat In Adults With Sickle Cell Disease Demonstrating Improvements In Anemia, Hemolysis And Sickling Parameters At 63rd ASH Annual Meeting And Exposition   Benzinga
07:00AM EST  Data Underscore Potential of Mitapivat to Provide Clinically Meaningful Outcomes for Patients   GlobeNewswire Inc
Dec 6, 2021
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Dec 3, 2021
10:17AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 3, 2021   Benzinga
06:32AM EST  B of A Securities Initiates Coverage On Agios Pharmaceuticals with Buy Rating, Announces Price Target of $54   Benzinga
Nov 18, 2021
11:56AM EST  SVB Leerink Maintains Market Perform on Agios Pharmaceuticals, Lowers Price Target to $42   Benzinga
Nov 15, 2021
04:01PM EST  Agios Appoints Richa Poddar as Chief Commercial Officer   GlobeNewswire Inc
Nov 4, 2021
06:39AM EDT  CENTOGENE To Provide Genetic Testing And Clinical Trial Support For Agios' Three Global, Pivotal Trials In Thalassemia And Sickle Cell Disease   Benzinga
06:35AM EDT  HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $95   Benzinga
06:30AM EDT  CENTOGENE Expands Partnership With Agios to Generate Novel   GlobeNewswire Inc
Nov 3, 2021
09:19AM EDT  The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering   Benzinga
09:16AM EDT  Agios Pharmaceuticals Q3 EPS $(1.56) Beats $(1.59) Estimate   Benzinga
09:10AM EDT  Earnings Scheduled For November 3, 2021   Benzinga
07:11AM EDT  Received FDA Priority Review for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency; PDUFA Date Set for Feb. 17, 2022   GlobeNewswire Inc
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 21, 2021
04:01PM EDT  Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced the company will host a conference call and live webcast on Wednesday, Nov. 3, 2021, at 8:00 a.m. ET to report its third quarter 2021 financial results and other business highlights.   GlobeNewswire Inc
Sep 2, 2021
10:14AM EDT  Agios Pharmaceuticals Sponsored Study Titled 'A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease' Posted To ClinicalTrials.gov, Shows Not Yet Recruiting   Benzinga
Aug 30, 2021
07:00AM EDT  Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that the company is scheduled to present at the following September investor conferences:   GlobeNewswire Inc
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
07:03AM EDT  Agios' Rare Anemia Drug Application Under FDA Priority Review   Benzinga
Aug 17, 2021
04:01PM EDT  Agios Announces FDA Acceptance And Priority Review Of New Drug Application For Mitapivat For Treatment Of Adults With Pyruvate Kinase Deficiency   Benzinga
04:01PM EDT  Agios Announces FDA Acceptance and Priority Review of New Drug   GlobeNewswire Inc
Jul 30, 2021
11:37AM EDT  HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $93   Benzinga
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 30, 2021   Benzinga
07:51AM EDT  Goldman Sachs Downgrades Agios Pharmaceuticals to Sell, Lowers Price Target to $39   Benzinga
Jul 29, 2021
08:18AM EDT  The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs   Benzinga
07:26AM EDT  Agios Pharmaceuticals Q2 EPS $(1.41), Inline   Benzinga
07:00AM EDT  Completed Regulatory Submissions for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. and EU   GlobeNewswire Inc
04:23AM EDT  Earnings Scheduled For July 29, 2021   Benzinga
Jul 25, 2021
10:05AM EDT  The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More   Benzinga
Jul 15, 2021
07:00AM EDT  Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that the company will host a conference call and live webcast onThursday, July 29, 2021at8:00 a.m. ETto report its second quarter 2021 financial results and other business highlights.   GlobeNewswire Inc
Jul 1, 2021
10:11AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2021   Benzinga
09:43AM EDT  UPDATE: Raymond James On Agios Market Perform Initiation: Firm Expects Stock To Remain Strong For Duration Of Share Repurchase Program But Believes That The Value Expected To Be Returned To Shareholders Is Already Reflected In The Share Price   Benzinga
04:58AM EDT  Raymond James Initiates Coverage On Agios Pharmaceuticals with Market Perform Rating   Benzinga
Jun 28, 2021
07:17AM EDT  Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency   Benzinga
07:08AM EDT  Agios Submits MAA To EMA For Mitapivat For Adults With Pyruvate Kinase Deficiency   RTTNews
07:00AM EDT  Agios Submits Marketing Authorisation Application to European   GlobeNewswire Inc
Jun 22, 2021
08:12AM EDT  The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal   Benzinga
07:00AM EDT  Agios Launches myAgios Patient Support Services for   GlobeNewswire Inc
Jun 21, 2021
11:07AM EDT  Agios Pharma Files US Application For Mitapivat In PK Deficiency   Benzinga
07:02AM EDT  Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency   Benzinga
07:00AM EDT  Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that it has submitted a New Drug Application (NDA) for mitapivat to the U.S. Food and Drug Administration (FDA) for the treatment of adults with pyruvate kinase (PK) deficiency.   GlobeNewswire Inc
Jun 11, 2021
03:00AM EDT  Study Met Primary Endpoint; Treatment with Mitapivat Induced Hemoglobin Increase of 1.0 g/dL in 16 of 20 (80%) Patients During Weeks 4-12   GlobeNewswire Inc
03:00AM EDT  Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in theU.S. This Quarterand in the EU in Mid-2021   GlobeNewswire Inc
Jun 10, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2021   Benzinga
08:13AM EDT  The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal   Benzinga
07:14AM EDT  HC Wainwright & Co. Initiates Coverage On Agios Pharmaceuticals with Buy Rating, Announces Price Target of $88   Benzinga
Jun 9, 2021
09:14AM EDT  The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US   Benzinga
Jun 8, 2021
09:17AM EDT  The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex   Benzinga
May 12, 2021
10:00AM EDT  Agios to Present Updated Data from Clinical Trials of Mitapivat in   GlobeNewswire Inc
Apr 30, 2021
08:14AM EDT  Canaccord Genuity Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $65   Benzinga
Apr 29, 2021
08:15AM EDT  The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx   Benzinga
07:35AM EDT  Agios Pharmaceuticals Q1 EPS $(1.31) Beats $(1.32) Estimate   Benzinga
07:00AM EDT  Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency and Phase 2 Study of Mitapivat in Thalassemia Accepted for Presentation at EHA 2021 Virtual Congress   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For April 29, 2021   Benzinga
Apr 24, 2021
09:24AM EDT  The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx   Benzinga
Apr 15, 2021
07:00AM EDT  Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that the company will host a conference call and live webcast on Thursday, April 29, 2021 at 8:00 a.m. ET to report its first quarter 2021 financial results and other business highlights.   GlobeNewswire Inc
Apr 1, 2021
07:18AM EDT  Agios Closes Sale Of Commercial, Clinical And Research-stage Oncology Portfolio To Servier   RTTNews
07:00AM EDT  Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio   GlobeNewswire Inc
Mar 25, 2021
04:02PM EDT  Agios Pharma Reports Shareholders Approved Sale Of Oncology Business to Servier   Benzinga
04:01PM EDT  Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that its shareholders voted to approve the previously disclosed sale of its commercial, clinical and research-stage oncology portfolio to Servier Pharmaceuticals, LLC, an independent global pharmaceutical company.   GlobeNewswire Inc
Mar 18, 2021
07:00AM EDT  Agios Sponsors Program Promoting Health Literacy for Patients with   GlobeNewswire Inc
Mar 1, 2021
10:14AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2021   Benzinga
07:05AM EST  Agios Submits Supplemental New Drug Application To FDA For TIBSOVO For Patients With Previously Treated IDH1-Mutant Cholangiocarcinoma   Benzinga
07:00AM EST  Agios Submits Supplemental New Drug Application to FDA for   GlobeNewswire Inc
05:56AM EST  JP Morgan Downgrades Agios Pharmaceuticals to Neutral, Announces $54 Price Target   Benzinga
Feb 26, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 26, 2021   Benzinga
07:00AM EST  In Partnership with the Sickle Cell Community Consortium, Agios Works to Address Educational Resource Gaps Caused by COVID-19 for Students with Sickle Cell Disease   GlobeNewswire Inc
06:10AM EST  SVB Leerink Downgrades Agios Pharmaceuticals to Market Perform, Lowers Price Target to $50   Benzinga
Feb 25, 2021
08:08AM EST  The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants   Benzinga
07:10AM EST  Agios Pharmaceuticals Q4 EPS $(1.41) Misses $(1.33) Estimate, Sales $44.05M Beat $40.17M Estimate   Benzinga
07:00AM EST  Strong Commercial Execution for Second Full Year of TIBSOVO with Fourth Quarter Net Revenue of$39.1Mand$121.1M for Full Year 2020   GlobeNewswire Inc
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 23, 2021
07:00AM EST  Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the following March investor conferences:   GlobeNewswire Inc
Feb 11, 2021
11:21AM EST  Stocks That Hit 52-Week Highs On Thursday   Benzinga
07:00AM EST  Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company will host a conference call and live webcast on Thursday, February 25, 2021 at 8:00 a.m. ET to report its fourth quarter and year end 2020 financial results and other business highlights.   GlobeNewswire Inc
Feb 10, 2021
07:34AM EST  The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs   Benzinga
Jan 27, 2021
07:36AM EST  The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement   Benzinga
06:30AM EST  SVB Leerink Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $55   Benzinga
Jan 26, 2021
04:01PM EST  37 Percent of Patients Treated with Mitapivat Achieved 33% Reduction in Transfusion Burden Compared to Individual Historical Transfusion Burden Standardized to 24 Weeks (1-Sided p=0.0002)   GlobeNewswire Inc
Jan 17, 2021
10:00AM EST  Agios Presents Final Data from Phase 3 ClarIDHy Study of   GlobeNewswire Inc
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 11, 2021
07:12AM EST  Agios Pharmaceuticals Announces 'Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. in Q2 2021 and in the EU in Mid-2021'   Benzinga
07:00AM EST  Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. in Q2 2021 and in the EU in Mid-2021   GlobeNewswire Inc
Jan 5, 2021
07:00AM EST  Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. ET.   GlobeNewswire Inc
Dec 28, 2020
09:57AM EST  Canaccord Genuity Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $57   Benzinga
Dec 21, 2020
10:28AM EST  Shares of Agios Pharmaceuticals, Inc. (AGIO) are currently gaining over 32% after the company announced plans to sell its cancer treatment business to Servier for up to $2 billion.   RTTNews
10:10AM EST  Biopharma M&A Continues: Agios Sells Oncology Portfolio, NantKwest's Reverse Merger With ImmunityBio, Eyegate Picks Up Panoptes   Benzinga
07:03AM EST  Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2B Plus Royalties   Benzinga
07:00AM EST  Agios to Dedicate All Resources to AdvancingMitapivat as a Potential Treatment for Three Initial Hemolytic Anemias and Building on its Scientific Expertise in Cellular Metabolism and PK Activation to Accelerate and Expand its Genetically Defined Disease Portfolio   GlobeNewswire Inc
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 9, 2020
09:45AM EST  Agios Pharmaceuticals shares were trading higher after SVB Leerink maintained an Outperform rating on the stock.   Benzinga
04:52AM EST  SVB Leerink Maintains Outperform on Agios Pharmaceuticals, Lowers Price Target to $61   Benzinga
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 7, 2020
04:33PM EST  Agios Reports Updated Data From Phase 1 Study Of Mitapivat In Sickle Cell Disease   Benzinga
04:30PM EST  Treatment with Mitapivat Induced Hemoglobin Increase of 1.0 g/dL in 6 of 11 (55%) Efficacy Evaluable Patients,Decreased Markers of Hemolysis, Reduced 2,3-DPG andIncreased ATP   GlobeNewswire Inc
Dec 6, 2020
08:41AM EST  Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace   Benzinga
Dec 1, 2020
07:17AM EST  Agios: Phase 3 ACTIVATE Trial Of Mitapivat Met Its Primary Endpoint   RTTNews
07:06AM EST  Agios Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved Its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused   Benzinga
07:00AM EST  40 Percent of Patients Treated with Mitapivat Achieved a Sustained Hemoglobin Increase of1.5 g/dLCompared to0 Placebo Patients (p<0.0001)   GlobeNewswire Inc
Nov 30, 2020
07:00AM EST  Agios Launches Anemia ID, a No-Cost Genetic Testing Program for   GlobeNewswire Inc
Nov 29, 2020
08:59AM EST  The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions   Benzinga
Nov 25, 2020
07:00AM EST  Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 at 2:00 p.m. ET.   GlobeNewswire Inc
Nov 13, 2020
07:40AM EST  The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations   Benzinga
Nov 12, 2020
04:59PM EST  Agios Says FDA Orphan Drug Designation Granted To Mitapivat For Treatment Of Sickle Cell Disease   RTTNews
04:37PM EST  Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease   Benzinga
03:36PM EST  Agios Shares Quiet Following FDA.gov AccessData Listing For Orphan Drug Designation Of Co.'s Sickle Cell Disease Treatment   Benzinga
Nov 5, 2020
08:23AM EST  Agios Pharmaceuticals: Q3 Earnings Insights   Benzinga
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
07:13AM EST  Agios Pharmaceuticals Q3 EPS $(1.43) Misses $(1.38) Estimate, Sales $34.71M Miss $38.02M Estimate   Benzinga
07:00AM EST  Third Quarter TIBSOVONet Revenue of$31.7 Million; Company Narrows 2020 TIBSOVONetU.S.Revenue Guidance to $113115 Million   GlobeNewswire Inc
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 4, 2020
06:16PM EST  Notable Earnings Watchlist For Thursday, Nov. 5, 2020 Before Market Open: MUR, ODP, WRK, REGN, ZTS, BLL, CAH, CIR, CBB, ABC, AGIO, AKBA, CMLS, AZN, HBI, CPRI, CNP, CNHI, CRON, GM, HII, NYT, PPL, MLCO, TEVA, BMY, BABA, AAWW, DUK, AMRN, CI, BDX   Benzinga
11:49AM EST  Agios To Present Broad Set Of Clinical And Translational Data For Oncology And Rare Genetic Disease Programs At The Virtual 2020 ASH Annual Meeting From Dec. 5 To Dec. 7   Benzinga
11:46AM EST  Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that a broad set of clinical and translational data from its oncology and rare genetic diseases programs will be presented at the American Society of Hematology (ASH) Annual Meeting being held virtually December 58, 2020.   GlobeNewswire Inc
Nov 2, 2020
08:59AM EST  Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 22, 2020
07:00AM EDT  Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, November 5, 2020 at 8:00 a.m. ET to report its third quarter 2020 financial results and other business highlights.   GlobeNewswire Inc
06:41AM EDT  Barclays Upgrades Agios Pharmaceuticals to Overweight, Announces $46 Price Target   Benzinga
Oct 19, 2020
12:32PM EDT  Needham Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $69   Benzinga
11:16AM EDT  Canaccord Genuity Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $70   Benzinga
11:13AM EDT  SVB Leerink Maintains Outperform on Agios Pharmaceuticals, Lowers Price Target to $67   Benzinga
08:25AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
07:43AM EDT  Piper Sandler Maintains Overweight on Agios Pharmaceuticals, Lowers Price Target to $73   Benzinga
Oct 16, 2020
04:05PM EDT  Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO As A Treatment for Relapsed Or Refractory IDH1-Mutant Acute Myeloid Leukemia   Benzinga
04:01PM EDT  Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO in Newly Diagnosed AML Patients   GlobeNewswire Inc
Sep 21, 2020
07:08AM EDT  Agios Pharma Says a Secondary Endpoint in its Phase 3 ClarlDHy Study of TIBSOVO Was Not Statistically Significant   Benzinga
07:00AM EDT  Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy   GlobeNewswire Inc
Sep 8, 2020
04:16PM EDT  Agios Appoints Jonathan Biller As CFO   RTTNews
04:01PM EDT  Agios Appoints Jonathan Biller as Chief Financial Officer, Head of   GlobeNewswire Inc
04:01PM EDT  Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs   Benzinga
Aug 27, 2020
07:00AM EDT  Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the virtual Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020 at 9:50 a.m. ET.   GlobeNewswire Inc
Aug 6, 2020
07:00AM EDT  Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020 at 1:00 p.m. ET.   GlobeNewswire Inc
Jul 31, 2020
08:16AM EDT  Cantor Fitzgerald Maintains Overweight on Agios Pharmaceuticals, Raises Price Target to $72   Benzinga
Jul 30, 2020
08:46AM EDT  Agios Pharmaceuticals Earlier Reported Q2 EPS $(1.31) Beats $(1.37) Estimate, Sales $37.35M Miss $37.71M Estimate   Benzinga
07:01AM EDT  Second Quarter TIBSOVONet Revenue of$27.6 Million; Company Reiterates 2020 TIBSOVONetU.S.Revenue Guidance of $105115 Million   GlobeNewswire Inc
04:06AM EDT  Earnings Scheduled For July 30, 2020   Benzinga
Jul 16, 2020
07:01AM EDT  Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, July 30, 2020 at 8:00 a.m. ET to report its second quarter 2020 financial results and other business highlights.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC